Timothy L Beard MD FACS, CPI
Chair Dept. of Surgery and medical Director of Research Bend memorial Clinic
Join to View Full Profile
1501 NE Medical Center DrBend, OR 97701
Phone+1 541-382-2811
Dr. Beard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Arizona College of Medicine-TucsonResidency, Surgery, 1994 - 1999
University of Wisconsin School of Medicine & Public HealthClass of 1994
Certifications & Licensure
OR State Medical License 1999 - 2025
AZ State Medical License 1995 - 1999
American Board of Surgery Surgery
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Publications & Presentations
PubMed
- A prospective, multicenter analysis of the integrated 31-gene expression profile test for sentinel lymph node biopsy (i31-GEP for SLNB) test demonstrates reduced numbe...J Michael Guenther, Andrew Ward, Brian J Martin, Mark Cripe, Rohit Sharma
World Journal of Surgical Oncology. 2025-01-03 - 20 citationsOliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory Analysis from Two Phase 3 Randomized Placebo ...Timothy L Beard, Cathy Michalsky, Keith A. Candiotti, Paul Rider, Linda Wase
Pain and Therapy. 2021-06-01 - 47 citationsAlvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: Economic analysis of a phase 4 randomized, co...Teresa L. Kauf, Robert S. Svatek, Gilad E. Amiel, Timothy L. Beard, Sam S. Chang
The Journal of Urology. 2014-06-01
Press Mentions
San Diego Biotech Secures FDA Approval for Drug That Soothes Pain After SurgeryMay 13th, 2021
3 Biotech Stocks Under $2 with Massive Upside PotentialApril 12th, 2020
Trevena Announces Positive Top-Line Results from Two Phase 3 Pivotal Efficacy Studies of Intravenous Oliceridine in Moderate-to-Severe Acute PainFebruary 21st, 2017- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
